Press releasePRNewswire
Cumberland Pharmaceuticals
CPIX · NASDAQ
$7.96+$1.26 (+18.81%)TodayMarket closed ·
Prev close $6.70
Latest news
- Press releasePRNewswire
CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- Press releasePRNewswire
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- Press releasePRNewswire
CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE
- Press releasePRNewswire
/C O R R E C T I O N -- Cumberland Pharmaceuticals Inc./
- Press releasePRNewswire
Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex
- NewsVandana Singh
Cumberland Pharma Advances Duchenne Program With New Safety, Efficacy Data
- Press releasePRNewswire
Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference
- Press releasePRNewswire
RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement
- Press releasePRNewswire
RedHill Biopharma Announces Up To $19.4 Million Private Placement
- Press releasePRNewswire
RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation
- Press releasePRNewswire
RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo
- Press releasePRNewswire
Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis
- Press releasePRNewswire
RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms
- Press releasePRNewswire
CUMBERLAND PHARMACEUTICALS ANNOUNCES LAUNCH OF VIBATIV® IN CHINA
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- News
Full Transcript: Cumberland Q1 2026 Earnings Call
- News
Cumberland Q1 Adj. EPS $(0.13) Down From $0.16 YoY, Sales $9.131M Down From $11.713M YoY
- News
Earnings Scheduled For May 5, 2026
- NewsAvi Kapoor
Why Sterling Infrastructure Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket
- Press releasePRNewswire
RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease
- Press releasePRNewswire
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE
- Press releasePRNewswire
RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights
- NewsAvi Kapoor
Crude Oil Gains Over 1%; US Initial Jobless Claims Edge Higher
- NewsAvi Kapoor
Dow Falls Over 200 Points; Tesla Shares Slip After Q1 Results
- Press releasePRNewswire
Cumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business with Apotex
- Press releasePRNewswire
RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026
- Press releasePRNewswire
CUMBERLAND PHARMACEUTICALS ANNOUNCES EXPANDED INDICATION FOR CALDOLOR® (IBUPROFEN) INJECTION AND LAUNCH OF NEW BRAND WEBSITE
- Press releasePRNewswire
Cumberland Pharmaceuticals Launches New Sancuso® Website Featuring Educational Resources for Chemotherapy-Induced Nausea and Vomiting
- Press releasePRNewswire
H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) | DelveInsight
- Press releasePRNewswire
CUMBERLAND PHARMACEUTICALS REPORTS 31% FOURTH QUARTER 2025 REVENUE GROWTH
- Press releasePRNewswire
CUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA®
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.